Continucare board approves listing on NYSE

Continucare Corporation (NYSE Amex: CNU) announced today that its Board of Directors has approved the listing of the Company's common stock on the New York Stock Exchange (NYSE). Subject to the Company's continued compliance with the NYSE's initial listing standards, the Company expects to begin trading on the NYSE on or about November 1, 2010 under its current stock symbol "CNU."

Richard C. Pfenniger, Jr., Continucare's Chairman and Chief Executive Officer, stated, "Our move to the NYSE exemplifies our focus on building shareholder value, and we look forward to joining the many leading companies that are a part of this exchange. We believe our association with the NYSE will further raise our visibility within the investment community as we continue to grow our business. We would also like to thank the NYSE Amex for its service and support over the years."

The Company has notified the NYSE Amex that it will voluntarily delist its common stock from the NYSE Amex. The Company expects the last day of trading of its common stock on the NYSE Amex to be on or about October 29, 2010. Until the Company's common stock begins trading on the NYSE, the Company's common stock will remain trading on the NYSE Amex under the stock symbol "CNU."

Source:

 Continucare Corporation

Posted in:

Tags:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.